10:51 AM EDT, 09/13/2024 (MT Newswires) -- OS Therapies ( OSTX ) said Friday it will develop two novel antibody drug conjugate therapeutic candidates to treat cancer using its proprietary SiLinker technology.

The first candidate targets breast, lung and gastric cancer, while the second one targets ovarian, fallopian tube and primary peritoneal cancer, the company said.

The candidates' therapeutic potential has been confirmed with the target engagement tests for both completed, the company said.

Price: 3.46, Change: -0.04, Percent Change: -1.20